In this study, once again PBMC from the healthy donor cohort responded to sCTLA-4 antibody blockade as before by producing significantly increased levels of both IFN-γ and IL-17, whereas PBMC from the melanoma patient cohort was slightly less responsive to sCTLA-4 blockade with regard to IFN-γ but not IL-17. Here, IFNG is linked to melanoma.